Archiv - September 2008
Immunogenicity and Safety Assessments After One and Two Doses of a Refrigerator-Stable Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children During the Second Year of Life
Schuster, Volker MD1; Otto, Walter MD2; Maurer, Lothar MD2; Tcherepnine, Patricia MD2; Pfletschinger, Ulrich MD2; Kindler, Klaus MD2; Soemantri, Peter MD2; Walther, Uta MD2; Macholdt, Ute MD2; Douha, Martine MSc3; Pierson, Patrice MSc3; Willems, Paul MD3
1 Hospital for Children and Adolescents, University
of Leipzig, Leipzig
2 Pediatric offices in Fulda, Frankenthal, Roding, Stuttgart, Trier, Kleve-Materborn, Berlin, Neuhaus am Rennweg, Germany
3 GlaxoSmithKline Biologicals, Rixensart, Belgium
Pediatr Infect Dis J. 2008 Aug;27(8):724-730
Background: Measles, mumps, and rubella (MMR)
and varicella (V) vaccines are often coadministered at 1 clinic
visit. This study (104389/NCT00127023) was undertaken to assess
the immunogenicity and safety of a new refrigerator-stable tetravalent
MMRV vaccine after 1 dose and after 2 doses administered during
the second year of life.
Methods: Nine hundred seventy healthy children aged 10–21 months received 2 doses of MMRV vaccine (Priorix-Tetra; GlaxoSmithKline Biologicals, Rixensart, Belgium) 42 days apart (MMRV group; N = 732) or 1 dose of MMR vaccine (Priorix) coadministered with varicella vaccine (Varilrix) followed by a second dose of only MMR vaccine 42 days later (MMR + V group; N = 238).
Results: Observed seroconversion rates for measles, mumps, rubella, and varicella antibodies 42 days postdose 1 were 94.5%, 96.1%, 99.7%, 95.5% in the MMRV group and 93.4%, 93.6%, 98.1%, 95.6% in the MMR + V group. Respective seroconversion rates postdose 2 were 98.3%, 99.4%, 99.7%, 99.7% in the MMRV group and 97.6%, 99.5%, 100%, 97.5% in the MMR + V group. Observed antimeasles and antimumps geometric mean titers (GMTs) were higher after each dose in the MMRV group than in the MMR + V group. Antivaricella GMT increased 21-fold in the MMRV group postdose 2, and was markedly higher than in the MMR + V group who did not receive a second dose of varicella (1903.3 and 80.3 dilution-1, respectively). Both vaccine regimens were generally well-tolerated in terms of local reactions, fever >39.5°C, and vaccine-related rashes.
Conclusions: Both after 1 dose and after 2 doses, the MMRV vaccine was at least as immunogenic as concomitant MMR and varicella vaccination suggesting that it could be suitable for use according to current vaccination schedules.